Advertisement

Revascularization benefits

New York, July 5, 2000 (Praxis Press) The 6-month results of the FRISC II (Fast Revascularisation during Instability in Coronary artery disease) invasive trial show a reduction in the composite endpoint of death or myocardial infarction, contradicting previous large-scale randomized trials. The recent one-year follow-up of this randomized trial published in the Lancet confirms that the invasive strategy rapidly transforms unstable coronary-artery disease into a stable condition, lowering long-te

July 6, 2000

New York, July 5, 2000 (Praxis Press) The 6-month results of the FRISC II (Fast Revascularisation during Instability in Coronary artery disease) invasive trial show a reduction in the composite endpoint of death or myocardial infarction, contradicting previous large-scale randomized trials. The recent one-year follow-up of this randomized trial published in the Lancet confirms that the invasive strategy rapidly transforms unstable coronary-artery disease into a stable condition, lowering long-term mortality and reintervention rate, myocardial-infarction risk, and the recurrence of angina and ischemia (see paper). Compared with non-invasive treatment strategy in 100 patients, the invasive approach saves 1.7 lives, prevents 2.0 non-fatal myocardial infarctions, and 20 re-admissions. These findings strongly suggest revascularization as the treatment of choice for most patients with unstable CAD with ischemia, or biochemical markers of myocardial damage.

Advertisement
BD Bioscience
BD Bioscience

Popular Now

  1. The Zombie Literature
    Features The Zombie Literature

    Retractions are on the rise. But reams of flawed research papers persist in the scientific literature. Is it time to change the way papers are published?

  2. First Data from Anti-Aging Gene Therapy
  3. Locating Language within the Brain
  4. The Two Faces of Fish Oil
    Notebook The Two Faces of Fish Oil

    The discovery of a tumor-protecting role for a fatty acid found in fish oil has sparked debate about the product’s safety.

Advertisement
Gilson
Gilson
Advertisement
LabX
LabX
RayBioTech